SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- LPL Financial LLC announced today that financial advisor Jason Wyatt, AWMA®, has joined LPL Financial’s broker-dealer, Registered Investment Advisor (RIA) and custodial platforms to launch Wyatt Wealth Management. He reported serving approximately $180 million in advisory, brokerage and retirement plan assets* and joins LPL from Wells Fargo Advisors. Based in Bryan, Texas, home to Texas A&M University, Wyatt was introduced to the financial services industry as a ...

Core Points - Stardust Power Inc. announced the exercise of an over-allotment option for an additional 1,100,000 shares, resulting in gross proceeds of approximately $220,000, bringing total gross proceeds from the offering to approximately $4.52 million [1][2] - The proceeds will support the completion of the Definitive Feasibility Study (DFS) for a lithium processing facility in Muskogee, Oklahoma, which is a critical step toward a Final Investment Decision (FID) [2] - The company aims to produce up to 50,000 metric tons per annum of battery-grade lithium, contributing to America's energy leadership and sustainable supply chains [5] Financial Details - The offering was managed by Aegis Capital Corp., and the registration statement was declared effective by the SEC on June 16, 2025 [3] - The offering's gross proceeds are before deducting underwriting fees and other estimated expenses [1] Strategic Importance - The strong investor interest in the offering reflects confidence in the company's business strategy, indicating a strategic and timely decision to advance its business plan [2] - Completing the DFS will provide detailed engineering and refined capital estimates, moving the project closer to construction financing [2]

Core Points - Canadian Life Companies Split Corp. has completed an overnight offering of Preferred Shares and Class A Shares, raising total gross proceeds of $40.0 million, increasing net assets to approximately $217.9 million [1][2] - The Preferred Shares were priced at $10.55 with a yield of 6.64%, while the Class A Shares were priced at $6.35 with a yield of 18.90% [2] - The net proceeds from the offering will be invested in an actively managed portfolio primarily consisting of four publicly traded Canadian life insurance companies: Great‐West Lifeco Inc., Industrial Alliance Insurance & Financial Services Inc., Manulife Financial Corporation, and Sun Life Financial Inc. [3]

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. has announced a public offering of 20 million shares of common stock and associated warrants, aiming to raise approximately $10 million to fund research and development activities and for general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes 20,000,000 shares of common stock and Series C and D warrants, priced at $0.50 per share, with total gross proceeds expected to be around $10 million before expenses [1]. - Series C Warrants and Series D Warrants will have an exercise price of $0.50 per share, with Series C Warrants expiring in five years and Series D Warrants expiring in 12 months [2]. - The closing of the offering is anticipated on or about June 27, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support research and development activities, working capital, and other general corporate purposes [3]. Group 3: Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [6]. - The company's pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house and protected by composition of matter patents in multiple regions [6].

Core Viewpoint - Jeffs' Brands Ltd has entered into a Securities Purchase Agreement to issue up to $100 million in convertible promissory notes, with an initial closing resulting in $4.5 million in gross proceeds from a $5 million note [1][3]. Group 1: Securities Purchase Agreement Details - The Company issued an initial $5 million Promissory Note for a purchase price of $4.5 million [1]. - The Company may request additional Promissory Notes of up to $2.5 million per quarter starting December 1, 2025, with a total limit of $50 million until that date and $25 million per quarter thereafter [3][4]. - Each Additional Promissory Note will be issued at a 10% original issue discount and will accrue interest at an annual rate of 4%, increasing to 14% upon default [5]. Group 2: Conversion and Repayment Terms - The Investor has the option to convert outstanding amounts under each Promissory Note into Ordinary Shares at a conversion price of either $6.80 per share or 88% of the lowest daily volume weighted average price during the preceding 20 trading days, subject to a 4.99% ownership limitation [6]. - Each Promissory Note is to be repaid in ten equal monthly installments starting 18 months after issuance [5]. Group 3: Company Strategy and Use of Proceeds - The net proceeds from the sale of the Promissory Notes will be used for working capital, general corporate purposes, and potential acquisitions to explore strategic opportunities [3]. - The Company is not obligated to issue any Additional Promissory Notes and there are no penalties or minimum drawdown requirements [7]. Group 4: Company Background - Jeffs' Brands aims to transform e-commerce by creating and acquiring products to become market leaders, leveraging insights into the Amazon FBA business model [9].

Company Overview - Coeptis Therapeutics Holdings, Inc. is a next-generation technology and biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [3][4] - The company has a therapeutic portfolio that includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy technology [4] - Coeptis is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and the Karolinska Institute [4] Recent Developments - Coeptis has filed a registration statement on Form S-4 with the SEC related to a proposed merger agreement with Z Squared Inc. [1][2] - The Form S-4 includes a preliminary proxy statement/prospectus regarding the proposed transaction, which has not yet become effective [2] Technology Division - Coeptis has established a Technology Division aimed at enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group [5] Z Squared Overview - Z Squared Inc. is focused on digital asset compute mining, primarily generating Dogecoin (DOGE) and other digital assets like Litecoin, with a market cap of $20 billion [7]

With reference to stock exchange notice of 14 May 2025 and partly remuneration to Mowi ASA’s shareholder-elected Board members in the form of shares. All Board members of Mowi have today purchased shares in the company as set forth below. The share purchases are pursuant to a recommendation from the Nomination Committee which was adopted by the General Assembly on 4 June 2025. The Nomination Committee is of the view that Directors on the Board of Mowi should be encouraged to invest in shares in the company, ...

LAS VEGAS, June 26, 2025 (GLOBE NEWSWIRE) -- Jet.AI Inc. ("Jet.AI" or the "Company") (Nasdaq: JTAI) and Consensus Core Technologies Inc. ("Consensus Core"), a provider of high-performance GPU infrastructure and AI cloud services, announced the execution of a definitive agreement to jointly develop a phased hyperscale data center campus in Midwestern Canada (the "Midwestern Project" or "Project"). The initiative positions Jet.AI as a pure-play AI data center enterprise targeting critical infrastructure short ...

Reduction in Force Estimated to Save Over $750K or 23.4% of Annual Payroll Expenses Agreements Progress Toward Completion; Shareholder Meeting Scheduled for July 24, 2025 IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced strategic headcount reduction and provided an update on the merger agreement with Vyome Therapeutics and asset purchase agreement with Biorad Medisys. “Whi ...

Spetner Reports 95% Revenue Growth and Tripled Net Income in Q1 2025, Highlighting Strong Profitability and Cash Flows Ahead of Planned AcquisitionLAKEWOOD, NJ, June 26, 2025 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (Nasdaq: RELI) (“Reliance,” “we,” “us,” “our” or the “Company”) today highlighted the strong preliminary unaudited financial results of Spetner Associates, Inc. (“Spetner”) for the first quarter ended March 31, 2025. As previously announced, Reliance has entered into a definitive agreemen ...